KRAS and non-small cell lung carcinoma: In a phase 1 trial on advanced or metastatic tumors with KRAS G12C mutations, Divarasib achieved an objective response rate (ORR) of 56.4% in non-small-cell lung cancer patients and a median progression-free survival (PFS) of 13.1 months.